There are tens of thousands of unmapped molecules circulating in human blood – thousands of which could represent robust biomarkers. Technologies to date have simply been too slow to map them efficiently.
Sapient’s nontargeted metabolomics lab and methods – powered by next-generation rapid liquid chromatography-mass spectrometry (rLC-MS) and a robust follow-on technology pipeline – are changing that, greatly enhancing the breadth and depth with which we can probe both known and unknown small molecule chemistries.
Download the fact sheet to see how Sapient leverages its high-powered methods to help researcher and biopharma sponsors rapidly identify and translate novel small molecule biomarkers.